The GORE® VIABIL® Biliary Endoprosthesis is a fully covered self-expanding metal stent intended for palliation of malignant strictures in the biliary tree. 

Unique anti-migration anchoring fin technology reduces the risk of reinterventions.a,1 

This self-expanding biliary stent provides the control and ease of use physicians demand and the outcomes they count on to deliver palliative care to their high-risk patients, supported through proven results. 
 

Improved treatment of biliary strictures

  • Precise placement made easy: Non-foreshorteningb design enables accurate deployment positioning.
  • Preferred2 balance of radial and axial forces provides the fit and flexibility to help minimize migration and sludge formation.c,2,3  
  • One stent, two delivery methods: Endoscopic and percutaneous delivery. The GORE® VIABIL® Biliary Endoprosthesis for endoscopic placement is also available in a short wire delivery system, the GORE® VIABIL® Short Wire Biliary Endoprosthesis.d
     

The outcomes you demand

Designed to reduce the risk of migration and premature obstruction, while sustaining long-term patency.

  • Demonstrated low migration rates: Fully covered anchoring fins securely hold the device within the duct to minimize the risk of migration. A meta-analysise,1 reported  0.1% - 1.7% migration rate range for GORE® VIABIL® Biliary Endoprosthesis and 2.6% - 8.1% migration rate range for BOSTON SCIENTIFIC® WALLFLEX® Biliary RX Fully Covered Stent.f
  • High Primary Patency: Prevents tissue ingrowth and promotes high primary patency rates for patients with malignant stricturesg,4,5

Endoscopic delivery: Contact your Olympus Sales Associate for support and product availability. Visit here for further support.  

Percutaneous delivery: Contact your Gore Sales Associate for support and product availability. Visit here for further support. 

a Data on file 2025; W. L. Gore & Associates, Inc; Flagstaff, AZ.  

b If deployed as instructed, the endoprosthesis will not appreciably foreshorten. 

c Benchtop evaluations are intended to demonstrate relative physical characteristics and may not correlate to clinical results. 

d Note: GORE® VIABIL® Short Wire Biliary Endoprosthesis is not licensed in Canada in accordance with the Canadian Medical Device Regulation SOR/98-282. 

e Data on file 2022; W. L. Gore & Associates, Inc; Flagstaff, AZ 

f Data is derived from a meta-analysis of published literature and is not intended to be a head-to-head comparison. 

g Data on file 2024; W. L. Gore & Associates, Inc; Flagstaff, AZ. 

h Anti-Migration Assurance Program specific to the U.S. only. 

  1. O'Neill F, Stevenson A, Swarup VP. Fully covered self-expanding metal stents for endoscopic retrograde cholangiopancreatography and percutaneous cholangiography in the management of malignant biliary obstruction: a U.S. cost-consequence analysis. Presented at DDW 2022 Digestive Disease Week; May 21-24, 2022; San Diego, CA. Gastrointestinal Endoscopy 2022;95(6)Supplement:AB293.
  2. Isayama H, Nakai Y, Toyokawa Y, et al.  Measurement of radial and axial forces of biliary self-expandable metallic stents. Gastrointestinal Endoscopy 2009;70(1):37-44.
  3. Isayama H, Mukai T, Itoi T, et al. Comparison of partially covered nitinol stents with partially covered stainless stents as a historical control in a multicenter study of distal malignant biliary obstruction: the WATCH study. Gastrointestinal Endoscopy 2012;76(1):84-92.
  4. Krokidis M, Fanelli F, Orgera G, Tsetis D, Mouzas I, Bezzi M, Kouroumalis E, Pasariello R, Hatzidakis A. Percutaneous palliation of pancreatic head cancer: randomized comparison of ePTFE/FEP-covered versus uncovered nitinol biliary stents. Cardiovascular & Interventional Radiology. 2011;34(2):352-361.
  5. Krokidis M, Fanelli F, Orgera G, Bezzi M, Passariello R, Hatzidakis A. Percutaneous treatment of malignant jaundice due to extrahepatic cholangiocarcinoma: covered Viabil stent versus uncovered Wallstents. Cardiovascular & Interventional Radiology 2010;33(1):97-106.

© 2025 W. L. Gore & Associates, Inc. All rights reserved. All trademarks referenced are trademarks of either a member of the Gore group of affiliated companies or their respective owners. “Together, improving life” mark and design are trademarks of a Gore company.

IFU Consult instructions

Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. RXOnly

FOR ENDOSCOPIC DELIVERY IN THE U.S.

INDICATIONS: (Non-Removable) The GORE® VIABIL® Biliary Endoprosthesis is indicated for palliation of malignant strictures in the biliary tree. 

CONTRAINDICATIONS: The GORE® VIABIL® Biliary Endoprosthesis is contraindicated for: ALL CARDIOVASCULAR APPLICATIONS; ducts less than 5.5 mm in diameter or greater than 9 mm in diameter.

FOR GORE® VIABIL® SHORT WIRE BILIARY ENDOPROSTHESIS FOR ENDOSCOPIC DELIVERY IN THE U.S.

INDICATIONS: (Non-Removable) The GORE® VIABIL® Short Wire Biliary Endoprosthesis is indicated for palliation of malignant strictures in the biliary tree.

CONTRAINDICATIONS: The GORE® VIABIL® Short Wire Biliary Endoprosthesis is contraindicated for. All CARDIOVASCULAR APPLICATIONS; ducts less than 5.5 mm in diameter or greater than 9 mm in diameter.

FOR PERCUTANEOUS DELIVERY IN THE U.S.

INDICATIONS: (Non-Removable) The GORE® VIABIL® Biliary Endoprosthesis is indicated for palliation of malignant strictures in the biliary tree.

CONTRAINDICATIONS: The GORE® VIABIL® Biliary Endoprosthesis is contraindicated for: ALL CARDIOVASCULAR APPLICATIONS; ducts less than 5.5 mm in diameter or greater than 9 mm in diameter.

FOR ENDOSCOPIC DELIVERY IN CANADA.

INDICATIONS: (Non-Removable): The GORE® VIABIL® Biliary Endoprosthesis is indicated for palliation of malignant strictures in the biliary tree. (Removable): The Removable GORE® VIABIL® Biliary Endoprosthesis is indicated for the treatment of benign and malignant biliary strictures and can be removed from such strictures for up to one year post implant.

CONTRAINDICATIONS: (Non-Removable): The GORE® VIABIL® Biliary Endoprosthesis is contraindicated for: ALL CARDIOVASCULAR APPLICATIONS; ducts less than 5.5 mm in diameter or greater than 9 mm in diameter. (Removable): The Removable GORE® VIABIL® Biliary Endoprosthesis is contraindicated for: ALL CARDIOVASCULAR APPLICATIONS; ducts less than 5.5 mm in diameter or greater than 9 mm in diameter and removal when positioned within a previously placed bare metal stent.

GORE® VIABIL® Short Wire Biliary Endoprosthesis is not authorized for use in Canada.

GORE® VIABIL® Biliary Endoprosthesis and GORE® VIABIL® Short Wire Biliary Endoprosthesis are not authorized for the treatment of benign biliary strictures and removability in U.S.

24GP1076-EN03